Stock Groups

FDA revises Lilly’s COVID-19 antibody combo EUA for use after exposure to virus By Reuters

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO A pharmaceutical manufacturing facility of Eli Lilly and Company is shown at 50 ImClone Drive, Branchburg, New Jersey. This photo was taken on March 5, 2021. REUTERS/Mike Segar

(Reuters) – The U.S. Food and Drug Administration said on Thursday it has revised its emergency use authorization for Eli Lilly (NYSE:)’s COVID-19 antibody cocktail to include for use after exposure to the virus in patients who are at high risk for progression to severe disease.

Bamlanivimab or etesevimab is approved for people aged 12 and over who have mild to moderate infection. They are also at risk of developing severe COVID-19.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. Instead, they are determined by marketmakers. As such, the prices might not reflect market conditions and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]